Sartorius and Repligen Corporation announced the launch of an integrated bioreactor system that incorporates Repligen XCell ATF upstream intensification technology into Sartorius’ Biostat STR bioreactor, simplifying intensified seed train and N perfusion implementation for biopharmaceutical manufacturers. The Biostat STR now contains a fully compatible embedded XCell ATF hardware and software module offering predefined advanced control recipes with integrated Process Analytical Technology. In addition, customers can better utilize facility space with a reduced equipment footprint from the incorporation of the XCell Controller hardware and software in the Biobrain automation platform, creating a single point of control for 50 L – 2000 L upstream intensification processes. The single, integrated controller provides easy integration into Supervisory Control and Data Acquisition and Distributed Control Systems.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RGEN:
- Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification
- Repligen price target lowered to $200 from $207 at Craig-Hallum
- Repligen price target raised to $200 from $180 at Stephens
- Repligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
- Repligen lowers 2023 adjusted EPS view $1.72-$1.80 from $2.35-$2.42